113 related articles for article (PubMed ID: 1775605)
1. Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type.
Raffaele KC; Berardi A; Asthana S; Morris P; Haxby JV; Soncrant TT
Psychopharmacol Bull; 1991; 27(3):315-9. PubMed ID: 1775605
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease.
Asthana S; Greig NH; Holloway HW; Raffaele KC; Berardi A; Schapiro MB; Rapoport SI; Soncrant TT
Clin Pharmacol Ther; 1996 Sep; 60(3):276-82. PubMed ID: 8841150
[TBL] [Abstract][Full Text] [Related]
3. Differential response to the cholinergic agonist arecoline among different cognitive modalities in Alzheimer's disease.
Raffaele KC; Asthana S; Berardi A; Haxby JV; Morris PP; Schapiro MB; Soncrant TT
Neuropsychopharmacology; 1996 Aug; 15(2):163-70. PubMed ID: 8840352
[TBL] [Abstract][Full Text] [Related]
4. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
Jenike MA; Albert MS; Heller H; Gunther J; Goff D
J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
[TBL] [Abstract][Full Text] [Related]
5. Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal memory and visuo-spatial function in dementia of the Alzheimer type.
Raffaele KC; Berardi A; Morris PP; Asthana S; Haxby JV; Schapiro MB; Rapoport SI; Soncrant TT
Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(5):643-8. PubMed ID: 1956992
[TBL] [Abstract][Full Text] [Related]
6. Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease.
Soncrant TT; Raffaele KC; Asthana S; Berardi A; Morris PP; Haxby JV
Psychopharmacology (Berl); 1993; 112(4):421-7. PubMed ID: 7871052
[TBL] [Abstract][Full Text] [Related]
7. Effects of oral physostigmine in Alzheimer's disease.
Stern Y; Sano M; Mayeux R
Ann Neurol; 1987 Sep; 22(3):306-10. PubMed ID: 3674795
[TBL] [Abstract][Full Text] [Related]
8. Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.
Chandra JN; Malviya M; Sadashiva CT; Subhash MN; Rangappa KS
Neurochem Int; 2008 Feb; 52(3):376-83. PubMed ID: 17719699
[TBL] [Abstract][Full Text] [Related]
9. Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type.
Sevush S; Guterman A; Villalon AV
J Clin Psychiatry; 1991 Jul; 52(7):300-3. PubMed ID: 2071560
[TBL] [Abstract][Full Text] [Related]
10. Lisuride treatment of Alzheimer's disease. A preliminary placebo-controlled clinical trial of safety and therapeutic efficacy.
Claus JJ; de Koning I; van Harskamp F; Breteler MM; Voet B; Gutzmann H; Dahlke F; van der Cammen T; Hofman A
Clin Neuropharmacol; 1998; 21(3):190-5. PubMed ID: 9617511
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine responses to intravenous infusion of arecoline in patients with Alzheimer's disease.
Asthana S; Raffaele KC; Greig NH; Berardi A; Morris PP; Schapiro MB; Rapoport SI; Blackman MR; Soncrant TT
Psychoneuroendocrinology; 1995; 20(6):623-36. PubMed ID: 8584603
[TBL] [Abstract][Full Text] [Related]
12. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM
Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268
[TBL] [Abstract][Full Text] [Related]
13. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
Filip V; Kolibás E
J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
[TBL] [Abstract][Full Text] [Related]
14. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
Stonnington CM; Snyder PJ; Hentz JG; Reiman EM; Caselli RJ
J Clin Psychiatry; 2009 Oct; 70(10):1379-84. PubMed ID: 19573495
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
16. Effects of donepezil on verbal memory after semantic processing in healthy older adults.
FitzGerald DB; Crucian GP; Mielke JB; Shenal BV; Burks D; Womack KB; Ghacibeh G; Drago V; Foster PS; Valenstein E; Heilman KM
Cogn Behav Neurol; 2008 Jun; 21(2):57-64. PubMed ID: 18541979
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
18. A neuropsychological test battery for use in Alzheimer disease clinical trials.
Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M
Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273
[TBL] [Abstract][Full Text] [Related]
19. Multiple-dose arecoline infusions in Alzheimer's disease.
Tariot PN; Cohen RM; Welkowitz JA; Sunderland T; Newhouse PA; Murphy DL; Weingartner H
Arch Gen Psychiatry; 1988 Oct; 45(10):901-5. PubMed ID: 3048224
[TBL] [Abstract][Full Text] [Related]
20. Effects of physostigmine and lecithin on memory in Alzheimer disease.
Peters BH; Levin HS
Ann Neurol; 1979 Sep; 6(3):219-21. PubMed ID: 534419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
